Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risperdal Consta on Health Care Utilization Costs in Schizophrenia
NCT00313391Phase 4
Key facts
- Status
- Completed
- Start
- Dec 2005
- Primary completion
- Dec 2007
- Countries
- 1
- Sponsor
- Emory University
- Modality
- Small Molecules
- Drugs
- risperidone
- Conditions
- schizophreniaschizoaffective disorder
01
Overview
Phase 4, open-label, single-arm trial of risperidone in schizophrenia and schizoaffective disorder, sponsored by Emory University. Primary endpoint: Total medical utilization costs at 1 year. Started Dec 2005; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Risperdal Consta
Patients treated with Risperdal Consta
03
Endpoints
Primary
Total medical utilization costs
Beyond the preview
Go deeper on NCT00313391.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00313391.